pamidronate and risedronic acid

pamidronate has been researched along with risedronic acid in 57 studies

Research

Studies (57)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (7.02)	18.2507
2000's	33 (57.89)	29.6817
2010's	16 (28.07)	24.3611
2020's	4 (7.02)	2.80

Authors

Authors	Studies
Bailey, BN; Docampo, R; Rodriguez, JB; Szajnman, SH	1
Bailey, BN; Caldera, A; Croft, SL; Docampo, R; Grimley, JS; Heath, HT; Kendrick, H; Lewis, JC; Lira, R; Martin, MB; Moreno, SN; Oldfield, E; Urbina, JA; Yardley, V	1
Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM	1
Martin, MB; Oldfield, E; Szabo, CM	1
Burzynska, A; Croft, SL; de Luca-Fradley, K; Grimley, JS; Kafarski, P; Kendrick, H; Lewis, JC; Martin, MB; Meints, GA; Oldfield, E; Olsen, JR; Sanders, JM; Van Brussel, EM	1
Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM	1
Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS	1
Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H	1
Chan, JM; Flessner, R; Gómez, AO; González-Pacanowska, D; Jennings, S; Kosztowski, T; Kotsikorou, E; Meints, GA; Morita, CT; Odeh, S; Oldfield, E; Papapoulos, SE; Raker, AM; Sanders, JM; Schwerdtfeger, C; Song, Y; van Beek, ER; Wang, H; Zhang, Y	1
Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G	1
Haase, C; Koscielski, LA; Leon, A; Oldfield, E; Song, Y; Studer, D; Zhang, Y	1
Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F	1
Abdou, WM; Ganoub, NA; Geronikaki, A; Sabry, E	1
Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG	1
Lombardo, F; Obach, RS; Waters, NJ	1
Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Docampo, R; No, JH; Nussenzweig, V; Oldfield, E; Singh, AP; Zhang, Y	1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A	1
Berlicki, Ł; Kafarski, P; Mucha, A	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Artyushin, OI; Brel, VK; Chuprov-Netochin, RN; Leonov, SV; Semenov, VV; Semenova, MN	1
Almeida Paz, FA; Barbosa, JS; Braga, SS	1
Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K	1
Licata, AA	1
Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN	1
Mundy, GR	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Blank, MA; Dierckman, TA; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN	1
Blank, MA; Gibson, GW; Lichtenberger, LM; Romero, JJ	1
Papapoulos, SE	1
Watts, NB	1
Bukowski, JF; Das, H; Kamath, A; Wang, L	1
Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R	1
Abrahamsen, B; Brixen, KT; Kassem, MS; Mosekilde, L	1
Orcel, P; Rousière, M	1
Franke, HR; Verdijk, R; Vermes, I; Wolbers, F	1
Aerts, K; Bridts, CH; Cos, P; De Clerck, LS; De Tollenaere, CB; Dombrecht, EJ; Ebo, DG; Schuerwegh, AJ; Stevens, WJ; Van Offel, JF	1
Langdahl, B; Mosekilde, L; Vestergaard, P	1
Klaushofer, K; Koller, B; Muschitz, C; Patsch, J; Pollhammer, I; Resch, H; Roschger, P	1
Mukherjee, S; Oldfield, E; Song, Y	1
Abelson, A	1
Silverman, SL	1
Geusens, P	1
Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M	1
Henry, C; Jahnke, W	1
Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y	1
Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R	1
Elahian, F; Lage, H; Mansouri, M; Mirzaei, SA; Mousavi, SS	1
Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T	1
Arponen, H; Haukka, J; Mäkitie, O; Valta, H; Vuorimies, I; Waltimo-Sirén, J	1
Amin, NL; James, RM; Phillips, R	1
Mészaros, Á; Veszelyné Kotán, E	2
Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM	1
Chen, Y; Huang, Y; Xiao, Y	1

Reviews

17 review(s) available for pamidronate and risedronic acid

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Bisphosphonates, Old Friends of Bones and New Trends in Clinics. Journal of medicinal chemistry, 2021, 02-11, Volume: 64, Issue:3 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans	2021
Bisphosphonate therapy. The American journal of the medical sciences, 1997, Volume: 313, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid	1997
Bisphosphonates as cancer drugs. Hospital practice (1995), 1999, May-15, Volume: 34, Issue:5 Topics: Antineoplastic Agents; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasm Proteins; Neoplasms; Osteolysis; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Risedronic Acid; Transforming Growth Factor beta	1999
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Annales de medecine interne, 2000, Volume: 151, Issue:6 Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Papio; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Time Factors	2000
Treatment of osteoporosis with bisphosphonates. Rheumatic diseases clinics of North America, 2001, Volume: 27, Issue:1 Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid	2001
[Pharmacological treatment of osteitis deformans (Paget's bone disease)]. Ugeskrift for laeger, 2005, Feb-28, Volume: 167, Issue:9 Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Radionuclide Imaging; Risedronic Acid	2005
[Paget's disease and its therapeutic management]. Presse medicale (Paris, France : 1983), 2005, Apr-23, Volume: 34, Issue:8 Topics: Administration, Oral; Alkaline Phosphatase; Biomarkers; Diphosphonates; Etidronic Acid; Follow-Up Studies; Humans; Infusions, Intravenous; Osteitis Deformans; Pamidronate; Remission Induction; Risedronic Acid; Time Factors; Treatment Outcome	2005
Fracture prevention in postmenopausal women. Clinical evidence, 2006, Issue:15 Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D	2006
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Pamidronate; Risedronic Acid; Risk Factors; Treatment Outcome; Zoledronic Acid	2008
Paget disease of bone: therapeutic options. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008, Volume: 14, Issue:5 Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Retreatment; Risedronic Acid; Treatment Outcome	2008
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Current osteoporosis reports, 2009, Volume: 7, Issue:1 Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Fractures, Bone; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid	2009
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis. PloS one, 2013, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome	2013
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia? Archives of disease in childhood, 2016, Volume: 101, Issue:3 Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteonecrosis; Pain; Pamidronate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risedronic Acid	2016
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid	2020

Other Studies

40 other study(ies) available for pamidronate and risedronic acid

Article	Year
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorganic & medicinal chemistry letters, 2001, Mar-26, Volume: 11, Issue:6 Topics: Animals; Bone Resorption; Diphosphonates; Fatty Acids; Humans; Inhibitory Concentration 50; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi; United States; United States Food and Drug Administration	2001
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. Journal of medicinal chemistry, 2001, Mar-15, Volume: 44, Issue:6 Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Diphosphonates; Leishmania donovani; Plasmodium falciparum; Structure-Activity Relationship; Toxoplasma; Trypanosoma brucei brucei; Trypanosoma cruzi; Vero Cells	2001
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. Journal of medicinal chemistry, 2002, May-23, Volume: 45, Issue:11 Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins	2002
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats	2002
Activity of bisphosphonates against Trypanosoma brucei rhodesiense. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Animals; Crystallography, X-Ray; Diphosphonates; Humans; Lethal Dose 50; Models, Molecular; Quantitative Structure-Activity Relationship; Quantum Theory; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Tumor Cells, Cultured	2002
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. Journal of medicinal chemistry, 2003, Nov-20, Volume: 46, Issue:24 Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid	2003
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. Journal of medicinal chemistry, 2004, Jan-01, Volume: 47, Issue:1 Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship	2004
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. Journal of medicinal chemistry, 2004, Jan-15, Volume: 47, Issue:2 Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha	2004
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium; Diphosphonates; Geranyltranstransferase; Humans; In Vitro Techniques; Leishmania major; Metatarsal Bones; Mice; Models, Molecular; Pyridinium Compounds; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; Trypanocidal Agents	2005
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9 Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis	2005
Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines. Journal of medicinal chemistry, 2006, Sep-21, Volume: 49, Issue:19 Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Pyridines; Quinolines; Structure-Activity Relationship; Terphenyl Compounds	2006
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin. Journal of medicinal chemistry, 2006, Dec-14, Volume: 49, Issue:25 Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes	2006
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles. European journal of medicinal chemistry, 2008, Volume: 43, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Diphosphonates; Granuloma; Hypersensitivity, Delayed; Inflammation; Mice; Rats; Structure-Activity Relationship; Thiazoles	2008
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. Journal of medicinal chemistry, 2008, Apr-10, Volume: 51, Issue:7 Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. Journal of medicinal chemistry, 2008, Sep-25, Volume: 51, Issue:18 Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Animals; Antimalarials; Diphosphonates; Hep G2 Cells; Humans; Liver; Mice; Models, Biological; Molecular Structure; Plasmodium berghei	2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR. European journal of medicinal chemistry, 2011, Volume: 46, Issue:1 Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics	2011
Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry. Journal of medicinal chemistry, 2011, Sep-08, Volume: 54, Issue:17 Topics: Amino Acid Motifs; Chemistry, Pharmaceutical; Humans; Organophosphonates; Phosphinic Acids	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. Bioorganic & medicinal chemistry letters, 2020, 12-01, Volume: 30, Issue:23 Topics: Acetamides; Animals; Antimitotic Agents; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Humans; Indoles; Sea Urchins; Solubility	2020
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:9 Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine	1991
Nonclinical model for assessing gastric effects of bisphosphonates. Digestive diseases and sciences, 1997, Volume: 42, Issue:2 Topics: Alendronate; Animals; Chelating Agents; Diphosphonates; Edetic Acid; Egtazic Acid; Etidronic Acid; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach	1997
Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:9 Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach; Structure-Activity Relationship	2000
Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Digestive diseases and sciences, 2000, Volume: 45, Issue:9 Topics: Alendronate; Animals; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Gastric Mucosa; Indomethacin; Male; Pamidronate; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Risedronic Acid; Surface Properties	2000
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood, 2001, Sep-01, Volume: 98, Issue:5 Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic Acid; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Interferon-gamma; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Monocytes; Multiple Myeloma; Neoplasms; Neoplastic Stem Cells; Osteoclasts; Osteoporosis; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Fusion Proteins; Risedronic Acid; Structure-Activity Relationship; T-Lymphocyte Subsets; Transfection	2001
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Calcified tissue international, 2004, Volume: 75, Issue:3 Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Tolerance; Etidronic Acid; Female; Humans; Injections, Intravenous; Male; Middle Aged; Osteitis Deformans; Pain; Pamidronate; Parathyroid Hormone; Risedronic Acid; Treatment Outcome	2004
Differential effects of bisphosphonates on breast cancer cell lines. Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2 Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid	2007
Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation. Biochemical and biophysical research communications, 2006, Sep-22, Volume: 348, Issue:2 Topics: Animals; Antioxidants; Boron Compounds; Cattle; Cells, Cultured; Chondrocytes; Clodronic Acid; Diphosphonates; Edetic Acid; Etidronic Acid; Ferrous Compounds; Flow Cytometry; Hydrogen Peroxide; Lipid Peroxidation; Pamidronate; Risedronic Acid; Simvastatin; tert-Butylhydroperoxide	2006
High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman. Wiener medizinische Wochenschrift (1946), 2007, Volume: 157, Issue:15-16 Topics: Absorptiometry, Photon; Accidental Falls; Administration, Oral; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Pamidronate; Risedronic Acid; Spinal Fractures; Thoracic Vertebrae; Time Factors; Treatment Outcome	2007
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model. Journal of the American Chemical Society, 2008, Jan-30, Volume: 130, Issue:4 Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid	2008
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid	2010
An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem, 2010, May-03, Volume: 5, Issue:5 Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid	2010
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection]. Se pu = Chinese journal of chromatography, 2012, Volume: 30, Issue:4 Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid	2012
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells. Biochimie, 2014, Volume: 99 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Etidronic Acid; Female; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasm Invasiveness; Pamidronate; Risedronic Acid; Zoledronic Acid	2014
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2014, Volume: 42, Issue:6 Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2014
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates. Journal of neurosurgery. Pediatrics, 2015, Volume: 15, Issue:3 Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infant; Kaplan-Meier Estimate; Logistic Models; Male; Osteogenesis Imperfecta; Pamidronate; Platybasia; Retrospective Studies; Risedronic Acid; Skull Base; Zoledronic Acid	2015
[Bisphosphonate use and related pharmaceutical issues II]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2016
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system. Scientific reports, 2023, 07-05, Volume: 13, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid	2023